Drug Profile
Immune globulin - CSL Behring
Alternative Names: Beriglobin P; Berirab P; Carimune NF; Gamma Venin P; Hizentra; human immunoglobulin G; IgNextGen 10%; IgPro10; IgPro20; Immune Globulin Subcutaneous [Human] 20% Liquid; IVIG 10% -CSL Behring; Privigen; Redimune; Redimune NF; Rhesogamma P; Rhophylac; Sandoglobulin; Sandoglobulin NF; ScIG; Subcutaneous immunoglobulin; Tetagam P; Varicellon; Venimmun N; VivaglobinLatest Information Update: 05 Jan 2024
Price :
$50
*
At a glance
- Originator CSL Behring
- Developer Assistance Publique Hopitaux de Paris; CSL Behring; Georgetown University; Rigshospitalet; University of Oxford
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Serum globulins; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Guillain-Barre syndrome; Haemolytic disease of newborn; Hepatitis A; Hepatitis B; Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Mucocutaneous lymph node syndrome; Rabies; Tetanus; Varicella zoster virus infections
- Phase III Dermatomyositis; Encephalitis; Renal transplant rejection
- Phase II Skin and soft tissue infections; Systemic scleroderma
- No development reported Lung transplant rejection; Motor neuron disease; Pelvic inflammatory disorders; Spinal cord injuries; Systemic lupus erythematosus
- Discontinued Diffuse scleroderma
Most Recent Events
- 05 Jan 2024 9407050 - Updated KDM and completed FE. Drug already launched. Boxed warning already covered
- 31 May 2023 Adverse events and pharmacokinetics data from phase-II trial in Systemic Scleroderma presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)
- 18 Apr 2023 CSL Behring plans to launch 50mL prefilled syringes of immune globulin for the treatment of Immunodeficiency disorders and Chronic inflammatory demyelinating polyneuropathy in the first quarter of 2024 (SC)